| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
Published online before print May 24, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
5 Blockade
,
,
,
From the Department of Ophthalmology,* University of Erlangen-Nürnberg, Erlangen; and Jerini AG,
Berlin, Germany
@ To whom correspondence should be addressed. E-mail: tinadie{at}gmx.net.
| Abstract |
|---|
The interaction between endothelial cells and extracellular matrix proteins plays an important role in (hem)angiogenesis. Integrins are able to mediate the outgrowth of newly formed blood vessels. In contrast, the role of integrins in lymphangiogenesis, ie, the outgrowth of new from pre-existing lymphatic vessels, has so far been unclear. Here, expression and functional relevance of integrins on lymphatic endothelium in vivo was investigated using the mouse model of combined inflammatory corneal hemangiogenesis and lymphangiogenesis. Immunohistochemistry revealed novel expression of both integrin
5 and
v on both resting and activated lymphatic vessels in vivo. Integrin
5-inhibiting small molecules significantly blocked the outgrowth of new lymphatic vessels into the cornea in a dose-dependent manner. The outgrowth of blood vessels was less significantly affected by this treatment, thus allowing for selective inhibition of lymphangiogenesis at lower dosages. Combined inhibition of integrin
5 and
v using inhibiting molecules did not significantly increase the anti-lymphangiogenic effect in vivo, thus suggesting an important functional role of integrin
5 in lymphangiogenesis. In summary, our findings demonstrate novel expression of specific integrins on growing lymphatic endothelial cells in vivo and reveal their functional role during lymphangiogenesis. This opens new treatment options for selective inhibition of lymphangiogenesis, eg, in oncology and transplant immunology.
This article has been cited by other articles:
![]() |
T. Dietrich, F. Bock, D. Yuen, D. Hos, B. O. Bachmann, G. Zahn, S. Wiegand, L. Chen, and C. Cursiefen Cutting Edge: Lymphatic Vessels, Not Blood Vessels, Primarily Mediate Immune Rejections After Transplantation J. Immunol., January 15, 2010; 184(2): 535 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
P Zimmermann, T Dietrich, F Bock, F K Horn, C Hofmann-Rummelt, F E Kruse, and C Cursiefen Tumour-associated lymphangiogenesis in conjunctival malignant melanoma Br J Ophthalmol, November 1, 2009; 93(11): 1529 - 1534. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-i. Kim, J. L. Chung, J. P. Hong, K. Min, K. Y. Seo, and E. K. Kim Bevacizumab Application Delays Epithelial Healing in Rabbit Cornea Invest. Ophthalmol. Vis. Sci., October 1, 2009; 50(10): 4653 - 4659. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Zahn, D. Vossmeyer, R. Stragies, M. Wills, C. G. Wong, K. U. Loffler, A. P. Adamis, and J. Knolle Preclinical Evaluation of the Novel Small-Molecule Integrin {alpha}5{beta}1 Inhibitor JSM6427 in Monkey and Rabbit Models of Choroidal Neovascularization Arch Ophthalmol, October 1, 2009; 127(10): 1329 - 1335. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okazaki, A. Ni, O. A. Ayeni, P. Baluk, L.-C. Yao, D. Vossmeyer, G. Zischinsky, G. Zahn, J. Knolle, C. Christner, et al. {alpha}5{beta}1 Integrin Blockade Inhibits Lymphangiogenesis in Airway Inflammation Am. J. Pathol., June 1, 2009; 174(6): 2378 - 2387. [Abstract] [Full Text] [PDF] |
||||
![]() |
E.-S. Chung, D. R. Saban, S. K. Chauhan, and R. Dana Regulation of Blood Vessel versus Lymphatic Vessel Growth in the Cornea Invest. Ophthalmol. Vis. Sci., April 1, 2009; 50(4): 1613 - 1618. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |